Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
Keywords :
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
location
Contact Email
Phone number
Website URL
Similar Companies1000
NodThera
NodThera is a biotech company that develops treatments for diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
LipUm
LipUm is a biotechnology company that offers anti-inflammatory drugs to alleviate symptoms of chronic inflammatory diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
Plexium
Plexium develops a targeted protein degradation platform for finding new therapies in cancer and other diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
GlobeImmune
GlobeImmune develops targeted molecular immunotherapy for cancer and infectious diseases using its proprietary Tarmogen® platform.
Sector
Subsector
Keywords
Location
total rounds
total raised
M&A Details1
Transaction name
Acquired by
Roche
announced date
price
Financials
Funding Rounds3
Number of Funding Rounds
Money Raised
Their latest funding was raised on 25.03.2019. Their latest investor Novartis Venture Fund. Their latest round Grant
Michael J. Fox Foundation
Michael J. Fox Foundation is a non-profit research firm dedicated to finding better treatments and a cure for Parkinson's disease.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Forbion
Netherlands-based venture capital firm investing in life sciences and MedTech companies.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Novartis Venture Fund
Novartis Venture Fund is a private equity and venture capital arm of Novartis AG.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Fountain Healthcare Partners
Fountain Healthcare Partners is an Irish-based life science venture capital fund.
Sector
Subsector
Location
count Of Investments
count Of Exists
Co-Investors
Investors4
Number of lead investors
Number of investors
Novartis Venture Fund
Novartis Venture Fund is a private equity and venture capital arm of Novartis AG.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Fountain Healthcare Partners
Fountain Healthcare Partners is an Irish-based life science venture capital fund.
Sector
Subsector
Location
count Of Investments
count Of Exists
Forbion
Netherlands-based venture capital firm investing in life sciences and MedTech companies.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Marco Boorsma
Marco is a Partner at Forbion Capital Partners investing in Life Science companies. He serves on the Board of RSPR Pharma and is an observer to the Board of Exosome Diagnostics and Oxyrane. He previously served on the Board of Dezima Pharma (sold to Amgen). Before joining Forbion, Marco was Business Development Director at DSM Pharmaceutical Products. Prior to DSM, Marco was a project manager and scientist at vaccine company Cytos Biotechnology (Switzerland). After obtaining a Master’s degree in molecular biology from the University of Groningen in the Netherlands, Marco received his Ph.D. in biotechnology from the ETH Institute for Technology in Zürich, Switzerland, and worked at the MRC Laboratory for Molecular Biology in Cambridge, UK.
current job
People
Founders2
Matthew Cooper
Dr. Matthew Cooper serves as Venture Partner at Forbion. Dr. Matthew Cooper serves as a Board Member at Gertrude Biomedical. Dr. Matthew Cooper Co-Founded and served as the Chief Executive Officer & Board Member at Inflazome. He holds a Ph.D. in Chemistry in 1995 then spent 13 years in the UK, first at the University of Cambridge, then 9 years in start-ups and biotechnology companies. He returned to academia in 2009 to work on therapies that block inflammation via modulation of the innate immune system, novel antimicrobials, rapid diagnostics and modulators of the human microbiome. He has advised and worked with venture capital, pharmaceutical and biotechnology companies worldwide was a co-founder, CSO and Director of Akubio, and the Founder and Managing Director of Cambridge Medical Innovations (acquired by Alere). He is currently a co-founder and Director of Defensin Therapeutics, Chair of the Scientific Advisory Board of Adenium Biotechnology. He has more than 20 patents and 200 scientific papers.
current job
organization founded
Matthew Cooper
Luke O'Neill
Luke O’Neill is a co-founder and director of Opsona Therapeutics. He was appointed to the Chair of Biochemistry at Trinity College Dublin in 2008, where he leads the Inflammation Research Group. In the same year, he was appointed Chair of the Immunity and Infection panel of the European Research Council. His research is in the area of the molecular basis to inflammatory diseases, with a particular interest in pro-inflammatory cytokines and Toll-like receptors. He has a PhD in Pharmacology from the University of London and has won numerous awards for his research, notably the Royal Irish Academy Medal for Biochemistry, the Irish Society for Immunology medal, the Royal Dublin Society/ Irish Times Boyle medal for Scientific Excellence and the Science Foundation Ireland Researcher of the Year Award 2009. He was elected a member of EMBO (the European Molecular Biology Organization) in 2005. He has published over 200 papers and reviews on his research, in journals such as Nature, Science, Cell, Nature Immunology, Nature Medicine, Nature Genetics and PNAS. His contribution to the field of immunology in Ireland and internationally can be seen from Ireland’s recent ranking as third in the world in terms of citations per paper (1999-2009), where seven of his publications were ranking in the top nine from Ireland since 2006.
current job
organization founded
Luke O'Neill
Employee Profiles2
Matthew Cooper
Chief Executive Officer & co-founder